Head-To-Head Contrast: Nuvectra (NASDAQ:NVTR) and Glaukos (NASDAQ:GKOS)

Glaukos (NYSE:GKOS) and Nuvectra (NASDAQ:NVTR) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their institutional ownership, risk, profitability, earnings, dividends, analyst recommendations and valuation.

Risk & Volatility

Glaukos has a beta of 1.66, suggesting that its stock price is 66% more volatile than the S&P 500. Comparatively, Nuvectra has a beta of 0.69, suggesting that its stock price is 31% less volatile than the S&P 500.

Profitability

This table compares Glaukos and Nuvectra’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Glaukos -8.60% -4.01% -2.83%
Nuvectra -99.08% -58.23% -34.01%

Institutional & Insider Ownership

75.2% of Nuvectra shares are held by institutional investors. 8.7% of Glaukos shares are held by insiders. Comparatively, 2.9% of Nuvectra shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings for Glaukos and Nuvectra, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Glaukos 1 2 5 0 2.50
Nuvectra 0 1 2 0 2.67

Glaukos currently has a consensus price target of $74.57, suggesting a potential upside of 24.41%. Nuvectra has a consensus price target of $10.67, suggesting a potential upside of 7,519.05%. Given Nuvectra’s stronger consensus rating and higher possible upside, analysts clearly believe Nuvectra is more favorable than Glaukos.

Earnings and Valuation

This table compares Glaukos and Nuvectra’s gross revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Glaukos $181.28 million 12.04 -$12.95 million ($0.37) -162.00
Nuvectra $48.83 million 0.05 -$48.13 million ($3.19) -0.04

Glaukos has higher revenue and earnings than Nuvectra. Glaukos is trading at a lower price-to-earnings ratio than Nuvectra, indicating that it is currently the more affordable of the two stocks.

Summary

Glaukos beats Nuvectra on 10 of the 14 factors compared between the two stocks.

Glaukos Company Profile

Glaukos Corporation, an ophthalmic medical technology and pharmaceutical company, focuses on the development and commercialization of surgical devices and sustained pharmaceutical therapies designed to treat glaucoma. It offers iStent, a micro-bypass stent for insertion in conjunction with cataract surgery for the reduction of intraocular pressure in adult patients with mild-to-moderate open-angle glaucoma; and iStent inject trabecular micro-bypass stent that allows the surgeon to inject stents into various trabecular meshwork locations through a single corneal entry for the reduction of intraocular pressure in mild-to-moderate open-angle glaucoma in combination with cataract surgery. The company's product pipeline includes iStent Infinite trabecular micro-bypass system, which is used as a standalone procedure in patients with refractory glaucoma; iStent Supra suprachoroidal micro-bypass stent that is designed to reduce intraocular pressure by accessing the suprachoroidal space in the eye; iStent SA trabecular micro-bypass system, a two-stent product, which uses a different auto-injection inserter designed for use in a standalone procedure; and iDose, a targeted injectable drug delivery implant that is designed to be pre-loaded into a small gauge needle and injected into the eye through a self-sealing corneal needle penetration. The company markets its products through direct sales force in the United States and other 16 countries, as well as through distribution partners in Europe, the Asia Pacific, Latin America, and internationally. Glaukos Corporation was founded in 1998 and is headquartered in San Clemente, California.

Nuvectra Company Profile

Nuvectra Corporation, a neurostimulation medical device company, develops and commercializes neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets. The company offers Algovita, a spinal cord stimulation system for the treatment of chronic intractable pain of the trunk and limbs. It is also developing Virtis, a sacral neuromodulation (SNM) system for the treatment of chronic urinary retention and overactive bladder; and technologies to support other indications, including SNM for the treatment of overactive bladder and deep brain stimulation to treat Parkinson's disease. The company serves hospitals, surgery centers, and medical facilities through a direct sales force and third-party distributors in the United States and Europe. Nuvectra Corporation was founded in 2008 and is headquartered in Plano, Texas.

Receive News & Ratings for Glaukos Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Glaukos and related companies with MarketBeat.com's FREE daily email newsletter.